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 DEVELOPMENT OF PANCREATIC CANCER ORGANOID MODEL FOR STUDYING 
IMMUNE RESPONSE IN PANCREATIC CANCER. Jin Woo Yoo, Prashanth R. Gokare, 
Yevgeniya Foster, Brittany Fitzgerald, Nikhil S. Joshi, James J. Farrell. Section of 
Gastroenterology, Department of Internal Medicine, Yale University, School of Medicine, New 
Haven, CT. 
The importance of immune system in pancreatic ductal adenocarcinoma (PDAC) 
pathogenesis and therapy remains poorly understood largely due to the lack of effective model 
systems. Cell lines are not physiologic as they cannot recapitulate the cancer stroma and lose 
genetic heterogeneity over time. Genetically engineered mouse models of PDAC are more 
physiologic than cell lines but lack neoantigens needed to mount T cell responses against tumor. 
Organoid models of PDAC offer unique opportunity to study immune mechanisms in PDAC 
since organoids can model complex layering of multiple cell types, creating a physiologically 
relevant system that is highly tractable for genetic manipulation, co-cultures, and high 
throughput assays. In this study, we sought to establish murine and human organoid models of 
PDAC to investigate the biology of PDAC immune response, with the specific aims of 
developing transplantable immunogenic murine PDAC organoid models for the study of antigen-
specific anti-tumor T cell responses and assembling a library of experimentally validated, 
patient-derived PDAC organoid lines for pancreatic cancer precision medicine research. 
To generate immunogenic murine organoid models of PDAC, pancreatic organoids were 
isolated from “KP-NINJA” (KrasLox-STOP-Lox-G12D; P53flox/flox; inversion induced joined 
neoantigen) mouse model that has been genetically engineered to express GFP-tagged T cell 
neoantigens derived from lymphocytic choriomeningitis virus in an inducible fashion. Isolated 
organoids were transformed in vitro using a lentiviral construct encoding Cre recombinase and 
 RFP reporter for expression of oncogenic KRAS and deletion of P53. A subset of transformed 
organoids was additionally treated with an adenoviral construct encoding FLPo recombinase to 
turn on neoantigen expression. Transformed organoids were combined with T cells in both in 
vivo and in vitro setting to assess for impact on tumor growth. Patient-derived PDAC organoids 
were generated using endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) specimens, 
surgical resection specimens, and tissues from patient-derived xenograft mouse models of 
PDAC. Established human organoid lines were validated by Sanger sequencing, tumor formation 
in vivo and immunohistochemistry of organoid-derived tumors. 
Subcutaneous injection of transformed murine PDAC organoids formed tumors in mouse 
that are histologically similar to early lesions found in human PDAC. Serial in vivo transfer of 
these organoids by performing sequential rounds of organoid generation from tumors derived 
from organoids formed progressively more advanced tumors. High level of neoantigen 
expression in 100% of cells comprising murine PDAC organoids resulted in rejection of tumor 
growth in mouse, while a low level of neoantigen expression restricted to 10% of cells permitted 
tumor growth with increased immune infiltration. Expression of neoantigens in T cell-PDAC 
organoid co-culture model systems promoted T cell infiltration of basement membrane matrix. 
Additionally, we generated 30+ patient-derived PDAC organoid lines using EUS-FNB and 
surgical specimens at Yale from 10/2017 to 5/2018.  
We have successfully established murine and human organoid models of PDAC from 
various tissues capturing discrete stages of PDAC progression. Our murine organoid models are 
uniquely equipped to study antigen-specific T cell responses against tumor. Ongoing work 
includes using CRISPR/Cas9-based lentiviral systems to define genes that impact anti-tumor T 
cell responses and using patient-derived organoids for precision medicine research.  
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CTGF Connective tissue growth factor 
EGF Epidermal growth factor 
ER Estrogen receptor 
ETC Electron transport chain 
EUS-FNB Endoscopic ultrasound-guided fine needle 
biopsy 
FGF Fibroblast growth factor 
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GFP Green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating 
factor 
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LCMV Lymphocytic choriomeningitis virus 
MCN Mucinous cystic neoplasm 
MDSC Myeloid-derived suppressor cell 
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RFP Red fluorescent protein 
rtTA Reverse tetracycline-controlled transactivator 
STAT3 Signal transducer and activator of transcription 3 
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TCR T cell receptor 
TGFα Transforming growth factor-α 
TIMP Tissue inhibitor of metalloproteinases 
TNFα Tumor necrosis factor-α 
TRE Tetracycline response element 
TSLP Thymic stromal lymphopoietin 
VEGF Vascular endothelial growth factor 
 
I.   INTRODUCTION 
Background 
Pancreatic ductal adenocarcinoma (PDAC; used interchangeably with pancreatic cancer 
hereafter), the predominant form of pancreatic malignancy, is currently the fourth leading cause 
of all cancer-related deaths in developed countries and is projected to become second only to 
lung cancer by year 2024.(1) In 2015 worldwide, 367,000 patients were newly diagnosed with 
pancreatic cancer, of whom 359,000 patients died due to pancreatic cancer-related causes within 
the same year.(2) Although surgical resection is currently the only curative treatment for 
pancreatic cancer, fewer than 20% of patients have resectable disease by the time their diagnosis 
is made. The overall survival rate at 5 years is less than 7%, with most of the survivors at 5 years 
belonging to the group of 10-20% of patients who undergo surgical resection of their tumors.(3) 
Even for those patients undergoing surgery, 80% of them eventually relapse and die from 
pancreatic cancer. 
The exceptionally poor prognosis of pancreatic cancer can be attributed to several 
factors.(2) First is its late diagnosis due to poor early detection, which is delayed by the absence 
of clear or disease-specific symptoms and the lack of reliable biomarkers for effective screening. 
Secondly, pancreatic cancer takes an aggressive course, with perineural and vascular invasions 
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and early distant metastases precluding a potentially curative surgical resection. Thirdly, 
pancreatic cancer displays remarkable resistance to conventional modalities of cancer therapy, 
including chemotherapy, radiotherapy as well as more recently developed molecularly targeted 
therapies including immunotherapy. Finally, pancreatic cancer harbors complex tumor biology 
with both intertumoral and intratumoral genetic heterogeneity, resulting in variable treatment 
responses from patient to patient thus rendering a generalized approach to therapy difficult. A 
comprehensive, mechanistic understanding of the pathophysiology underlying pancreatic cancer 
is fundamental to overcoming these barriers. 
Cell of Origin 
The normal pancreas consists of two distinct functional components: endocrine and 
exocrine. The endocrine component consists of glucagon-producing alpha cells and insulin-
producing beta cells that are anatomically organized into islets, and can give rise to a relatively 
rarer form of pancreatic malignancies termed pancreatic neuroendocrine tumors, which have 
been found to harbor mutational signatures clearly distinct from those of PDAC. These 
signatures include inactivation of genes MEN1, ATRX and DAXX, derangements in the mTOR 
signaling pathway, recurrent YY1 Thr372Arg missense mutations, and biallelic MUTYH 
inactivating mutations.(4) 
The exocrine component of the pancreas consists of digestive enzyme-secreting acinar 
cells and bicarbonate-secreting ductal cells. Historically, ductal cells were thought to be the 
unique source of PDAC, given their co-expression of epithelial markers, such as CK19. Recent 
studies using genetically engineered mouse models of PDAC have shown that in fact both ductal 
and acinar cells can give rise to PDAC precursor lesions by oncogenic KRAS activation.(4) 
Furthermore, transient acinar-to-ductal metaplasia was observed in mouse models, with 
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reversible phenotypic and molecular changes that persisted in the presence of chronic 
inflammation or oncogenic KRAS activation. Although there is also evidence for this 
phenomenon in resected human PDAC surgical specimens, it has been argued that the 
metaplastic lesions may be intraductal spread of pre-existing PDAC and/or its precursor lesions. 
Genetic Landscape of Pancreatic Cancer 
The genetic landscape of PDAC is characterized predominantly by mutations in four 
major driver genes, listed in the order of decreasing frequency: KRAS, CDKN2A, SMAD4, and 
TP53. Frequent alterations in these genes were first identified by candidate gene sequencing and 
have since been corroborated repeatedly by multiple large exome and genomic sequencing 
studies of PDAC.(5) Activating mutations of oncogene KRAS are seen in more than 90% of 
PDACs, and inactivating mutations of tumor suppressor genes, CDKN2A, SMAD4 and TP53 in 
50-80% of PDACs.(2) An additional 32 recurrent ‘passenger’ mutations – defined as those co-
occurring with driver mutations without conferring additional growth advantage – were also 
identified, including but not limited to ARID1A, RNF43, TGFBR1, TGFBR2, MLL3, MKK4, 
KDM6A, PREX2, RB1 and CCND1, at lower frequencies in approximately 10% of PDAC 
tumors, highlighting the significance of tumoral heterogeneity (Table 1).(2, 4) It will be 
important to fully characterize the functional significance of these passenger gene mutations as 
they represent genetic differences among PDACs that may be exploited clinically. 
Precursor Lesions 
At least three histologically distinct precursor lesions of PDAC have been described so 
far, consisting of pancreatic intraepithelial neoplasm (PanIN), and two types of mucinous cystic 
lesions including intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic 
neoplasm (MCN). These precursor lesions are further characterized histologically and graded 
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according to their degree of dysplasia as lesions of low-grade versus high-grade dysplasia 
(Figure 1). 
Targeted sequencing of PanIN lesions along with their matched corresponding PDAC 
surgical resection specimens demonstrated that the same four driver genes are mutated in PanIN 
at very high frequencies as observed in PDAC. Comprehensive exome and whole genomic 
sequencing studies also confirmed these findings, establishing PanIN as the canonical precursor 
lesion of PDAC.(5) Similarly, shared mutations were also seen with mucinous cysts and their 
matched corresponding PDACs. Targeted sequencing of IPMNs identified shared mutations in 
genes GNAS and KRAS, and exome sequencing of IPMNs and MCNs identified shared 
mutations in RNF43, indicating that cystic neoplasms represent additional precursor lesions of 
PDAC that employ different progression pathways.(4)  
Remarkably, mutational analysis comparing PanINs of different grades revealed a 
positive correlation between the PanIN grade and the frequencies at which driver gene mutations 
are found.(5) Furthermore, it revealed a sequential pattern in which mutations found to 
accumulate in a predictive order following the PanIN grade. High-sensitivity methods to detect 
KRAS mutations showed their involvement in more than 99% of all PanIN-1 lesions, suggesting 
that oncogenic transformation of KRAS is most likely the initiating step in the development of 
pancreatic cancer.(6) While KRAS mutations are found across all grades of PanINs and invasive 
PDACs, the proportion of cells harboring the mutation increases with higher PanIN grade, 
indicating a clonal expansion of cells carrying the mutation.(6) In addition to oncogenic KRAS, 
inactivating mutations in CDKN2A can be seen in PanIN-2 and again at a higher frequency in 
PanIN-3.(5) Similarly, SMAD4 and TP53 mutations are additionally found in PanIN-3 and in 
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invasive PDACs, with both SMAD4 and TP53 mutations occurring at higher frequencies in 
invasive PDACs. 
These findings may be explained by a linear progression model of pancreatic cancer 
development, in which mutations are acquired in a gradual, step-wise pattern. By sequencing 
primary PDACs and their matched metastatic tumors, it was estimated that the linear progression 
from a nascent pancreatic cell acquiring an initiating driver gene mutation to the ultimate 
development of invasive PDAC would take 10 or more years.(7) This notion is consistent with 
the observation that nearly 33% of pancreata seen in autopsy series contain PanINs, suggesting 
that PanINs are quite common and generally do not progress to an invasive cancer.(6) In 
contrast, an alternative model termed chromothripsis proposes a punctuated evolution of 
pancreatic cancer, in which catastrophic genomic events involving structural alterations cause 
simultaneous inactivation of multiple driver genes in a single cell cycle. In support of this model, 
whole genome sequencing of primary tumors demonstrated two-thirds of PDACs having 
complex structural variations that, in a subset of cases, simultaneously inactivated multiple driver 
genes.(8) In the same study, many tumors did not harbor the predicted sequence of mutations, 
suggesting that these mutations may be acquired in a stochastic fashion consistent with a 
chromothripsis model. Still, a third model that combines both linear progression and punctuated 
evolution is entirely plausible. Distinguishing among these mechanistically distinct yet mutually 
non-exclusive models has clinical importance, since under a linear progression model which 
predicts a slow and gradual progression of disease, clinical efforts are best geared toward 
improving methods for screening and early detection of pancreatic cancer, whereas under a 
punctuated evolution model, an emphasis on enhancing systemic therapy is more appropriate. 
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Mutational Processes 
To fully understand the pathophysiology of PDAC, it is essential to delineate the 
mutational processes that are operative in the development of PDAC. Framing pancreatic cancer 
in familiar evolutionary terms can facilitate a mechanistic understanding of how mutations arise 
in the first place. In Darwinian evolution, mutations occur purely stochastically in dividing cells 
at an expected somatic mutation rate of three single nucleotide variants per cell division.(6) In 
the case of the pancreas which does not comprise of highly proliferative tissues, the probability 
of a pancreatic cell acquiring an initiating driver gene mutation by random chance alone is 
exceedingly low, and can be expected to largely depend on the total number of cell divisions 
performed over the lifetime of the dividing cell. Not surprisingly, statistical analysis of various 
types of human cancers, including PDAC, revealed a strong correlation between lifetime cancer 
risk and the number of cell divisions performed by adult stem cells of a given organ.(9) This 
finding lends support to the well-established finding that patient age is a major risk factor for the 
development of PDAC. Indeed, most pancreatic cancer patients are diagnosed at beyond age 50, 
with peak incidence occurring in the seventh and eighth decades of life.(2) However, the relative 
contribution of intrinsic factors (e.g. stochastic mistakes taking place during DNA replication) 
versus extrinsic factors (e.g. patient exposure to carcinogens or radiation) to lifetime risk remains 
a point of contentious debate.  
By whole-genome and RNA sequencing of resected PDAC surgical specimens, Connor 
et. al identified four distinct mutational processes acting on the PDAC genome.(4, 10) Those 
related to increasing age and number of cell divisions were the most prevalent, accounting for 
approximately 70% of all mutational signatures observed. To lesser degrees, mismatch repair 
(MMR) defects accounted for 2%, homologous recombination (HR) defects accounted for 11%, 
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and a process of unknown etiology termed “Signature 8” accounted for 15% of the mutational 
signatures. Tumors with MMR and HR defects characteristically showed biallelic inactivation of 
genes essential for the respective DNA repair processes, including MSH2, BRCA1, BRCA2 and 
PALB2. Also, one allele was often lost in the germline, which explains the involvement of the 
same genes in familial pancreatic cancers. Of note, tumors with MMR defects, owing to their 
microsatellite instability, exhibited higher burdens of somatic mutations and increased 
transcription of antitumor immune markers as determined by RNA sequencing, which may 
translate to a greater responsiveness to immunotherapy. 
Tumoral Heterogeneity 
The complex genetic landscape of PDAC is complicated by significant tumoral 
heterogeneity, which can be further categorized into intratumoral and intertumoral heterogeneity.  
Intratumoral heterogeneity, which describes genetic heterogeneity that exists among cells 
of a single tumor, is a well-recognized prognostic factor and an important cause of therapeutic 
resistance in pancreatic cancer. The concept of intratumoral heterogeneity first became apparent 
in lineage tracing studies of primary PDACs and matched metastatic tumors, which determined 
that metastatic tumors arise from distinct subclonal outgrowths from the primary lesion, all of 
which likely diverged from a single parental clone.(7) Intratumoral heterogeneity in a patient can 
manifest in three forms: [1] subclonal heterogeneity within a primary tumor, where a founder 
clone gives rise to various subclones by acquiring additional mutations, [2] subclonal 
heterogeneity within a metastasis, where a metastasis-initiating cell gives rise to its descendant 
subclones in a similar fashion, and [3] subclonal heterogeneity of metastasis-initiating cells 
within a primary tumor, where metastasis-initiating cells share common ancestors but possess 
distinct mutations that confer varying degrees of metastatic potential.(6) 
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Intertumoral heterogeneity describes genetic heterogeneity that exists among tumors of 
same histological type occurring in different patients, and it has been well-described in 
pancreatic cancer. To characterize the intertumoral differences systematically, several 
classification systems have been proposed based on genomic, transcriptomic, and 
immunohistochemical analyses.  
Molecular Subtyping of Pancreatic Cancer 
Waddell et al. classifies PDAC into four major subtypes based on patterns of structural 
variation identified from their genomic analysis.(11) In their study, 20% of tumors had ‘stable’ 
genomes with fewer than 50 structural variants, 36% of tumors had ‘scattered’ structural events 
with 50-200 variants, 14% of tumors had ‘unstable’ genomes with more than 200 structural 
variants suggestive of defects in DNA maintenance, and lastly, 30% of tumors had a ‘locally 
rearranged’ pattern with fewer than 50 structural variants localized to 1-3 chromosomes which 
typically result from amplifications that encompass oncogenes or genomic catastrophes such as 
in the case of chromothripsis. Interestingly, the ‘unstable’ subtype was predictive of platinum 
and poly (ADP-ribose) polymerase (PARP) inhibitor responsiveness.  
Transcriptomic studies of PDAC have also identified different molecular subtypes of 
PDAC with prognostic and therapeutic implications, resulting in a number of classification 
systems that differ based on the input material used and assumptions made for each study. Using 
microarray expression analysis of microdissected epithelium, Collison et al. classifies PDAC into 
three subtypes termed ‘classical’, ‘quasimesenchymal’ and ‘exocrine-like’.(12) Notably, the 
classical subtype was predictive of therapeutic response to erlotinib, while the 
quasimesenchymal subtype was negatively prognostic and predictive of therapeutic response to 
gemcitabine. In a similar study, Bailey et al. analyzed transcriptomic data from bulk tissue 
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containing the tumor microenvironment, and identified an additional ‘immunogenic’ subgroup 
based on presence of stromal immune cell populations.(13) Still, Moffitt et al. proposed a new 
classification system by excluding transcripts from presumed normal pancreas from their 
analysis, and identified two tumoral subtypes – ‘classical’ versus ‘basal-like’ – as well as two 
stromal subtypes – ‘normal’ versus ‘activated’.(14) Tumors corresponding to ‘basal-like’ 
subtype and ‘activated’ stromal subtype were independently and additively negatively 
prognostic. The basal type was also more responsive to chemotherapy on retrospective analysis.  
Although large-scale genomic and transcriptomic analyses have greatly elucidated the 
intertumoral heterogeneity of PDAC defining its molecular subtypes and established a 
foundation for developing precision medicine, applying this knowledge clinically has been 
limited by the common lack of access to complex tumor tissue biobanking and sequencing 
platforms for most clinicians. To this end, Noll et al. asked whether immunohistochemical (IHC) 
analysis, which is a far more accessible and technically feasible form of testing for clinicians at 
large, could be used to subtype pancreatic tumors by protein expression, and determined two 
IHC markers – HNF1A and KRT81 – for the differentiation of Collison subtypes.(15) 
Specifically, HNF1A-positive tumors correlated to the exocrine-like subtype, KRT81-positive 
tumors to quasimesenchymal subtype, and IHC-negative tumors to classical subtype. In addition, 
their study identified CYP3A expression as a novel mechanism of drug resistance, found at 
higher levels in exocrine-like tumors but inducible in all subtypes.   
In 2009, Farrell et al. reported the predictive value of an IHC-based assay for guiding 
precision medicine treatment of pancreatic cancer. In a phase III adjuvant therapy trial of 538 
patients with early pancreatic cancer, the expression of human equilibrative nucleoside 
transporter (hENT1) – a key mediator of cellular uptake of gemcitabine – measured by IHC 
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analysis of tumor microarrays was associated with increased overall survival and disease-free 
survival in patients who received gemcitabine, but not in those who received 5-FU, 
demonstrating hENT1 as a predictive biomarker for gemcitabine efficacy in patients with early 
pancreatic cancer.(16)  
Deranged Signaling Pathways / Molecular Aberrations 
The full mutational landscape of pancreatic cancer is highly complex and diverse. 
PDACs contain an average of 63 genetic alterations, the majority of which consists of infrequent 
mutations found in fewer than 10% of PDACs.(2, 17) Nonetheless, many cases of these low-
frequency targets appear to be alternative perturbations of the same core signaling pathways that 
are commonly deranged across all PDAC subtypes. By interrogating the exome of 24 PDACs, 
Jones et al. determined 12 core signaling pathways consistent with the hallmarks of cancer 
previously described by Hanahan and Weinberg, although the specific genes and the number of 
genes altered in each pathway differed from patient to patient.(17, 18) Included among the 
pathways were those affected by well-known driver genes, such as TP53 in DNA damage 
response and SMAD4 in TGFβ signaling. Some pathways, such as RAS-ERK signaling and 
DNA damage response, were predominated by a single frequently mutated gene, while others, 
such as integrin signaling, regulation of invasion, homophilic cell adhesion and GTPase-
dependent signaling, involved many different genes. Biankin et al. further enriched our 
knowledge of commonly deranged pathways by next-generation exome sequencing, shedding 
light on the deregulation of axon guidance (SLIT and ROBO2), DNA damage repair (ATM) and 
chromatin modification (EPC1) in PDAC, which were formerly unappreciated.(19) 
Aberrant autocrine and paracrine signaling cascades ultimately promote pancreatic cancer 
cell proliferation, migration, invasion, and metastasis.(2) Numerous cytokines, such as 
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transforming growth factor-α (TGFα), insulin-like growth factor 1 (IGF1), fibroblast growth 
factors (FGFs) and hepatocyte growth factor (HGF), and their respective tyrosine kinase 
receptors, lead to pathologic activation of multiple pathways that confer pancreatic cancer cell 
mitogenic self-sufficiency. These signaling cascades also act to promote cancer cell migration 
and invasion of both local and distant sites, leading to metastasis. Pancreatic cancer cell 
proliferation is further enhanced by pathologic activation of anti-apoptotic and pro-survival 
pathways, such as signal transducer and activator of transcription 3 (STAT3), nuclear factor-κB 
(NF-κB) and AKT. Reactivation of genes involved in early development, such as WNT, SHH 
and NOTCH, can also be seen in a subset of PDAC. 
Pathway derangements in PDAC are numerous, and deconstructing their downstream 
effects is further complicated by significant crosstalk between pathways creating synergistic 
outcomes.(6) p53 normally cooperates with receptor SMADs to activate TGFβ-induced 
transcription by forming complexes that bind separate cis-enhancer elements on a target gene 
promoter. In PDAC, oncogenic KRAS interferes with TGFβ signaling by degrading SMAD4 and 
inhibiting p53 by blockade of its amino-terminal phosphorylation. Furthermore, oncogenic 
KRAS and mutant p53 form pathologic complexes that in turn inhibit p63, which normally acts 
to oppose TGFβ-dependent cell migration, invasion and metastasis. Collectively, these findings 
indicate that deranged pathways in pancreatic cancer exist not as independent processes but 
rather as a complex tumorigenic network altering the systems biology of the cell.(6)  
Tumor Microenvironment 
A hallmark of PDAC is its abundant and dense collagenous stroma, which may account 
for up to 90% of the total tumor volume. The tumor microenvironment of PDAC consists of a 
highly complex assembly of diverse cell types, including pancreatic stellate cells (PSCs), 
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immune cells, endothelial cells and nerve fibers, which are influenced by the extracellular matrix 
composed of matricellular proteins, fibrillar collagen, fibronectin, hyaluronic acid and a wide 
range of cytokines, such as TGFβ, FGF, epidermal growth factor (EGF) receptor ligand, vascular 
endothelial growth factor (VEGF) and connective tissue growth factor (CTGF). 
There is now abundant evidence for the prominent role of pancreatic cancer-associated 
stroma in tumor progression by actively promoting tumor growth, invasion and metastasis. 
Recently, a protective effect of some of the stromal components contributing to a physical 
containment of cancer cells has also been suggested. The dual function of PDAC stroma as both 
a tumor promoter and a suppressor suggests that its pathogenic role may arise from a loss of 
balance between epithelial cells and stroma. While normal extracellular matrix has the capacity 
to restrain tumor growth through the histone demethylase JMJD1a, desmoplastic stroma consists 
of aberrant matrix that is stiff with thickened collagen fibers and expresses p-MLC2 that 
contributes to tumor progression.(20, 21) PSCs are major drivers of the desmoplastic reaction in 
PDAC, wherein pancreatic tissue injury leads to PSC activation and trans-differentiation into α-
smooth muscle actin expressing myofibroblast-like cells secreting collagen-type I, matrix 
metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) that remodel the 
extracellular matrix. PSC activation can be triggered by various cytokines and stimuli, including 
platelet-derived growth factor (PDGF), TGFβ1, FGF, EGF, tumor necrosis factor-α (TNFα), 
interleukin-1 (IL-1), ethanol, endotoxins, hypoxia, pressure and oxidative stress, many of which 
are produced by pancreatic cancer cells, endothelial and immune cells of the microenvironment. 
Once established, PSC activation is maintained in an autocrine fashion. The resulting fibrous 
stroma is a severely hypoxic, nutrient-deprived environment that promotes tumor aggressiveness 
by activation of hypoxia-inducible factor-1a. In addition, activated PSCs directly promote 
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proliferation of cancer cells by secreting mitogenic factors such as stromal-derived factor-1, 
PDGF, EGF, IGF-1 and FGF which activate MAPK- and AKT-signaling cascades.(22) 
Another key feature of the PDAC microenvironment is its highly immunosuppressive 
composition. Once the tumor is established, the tumor microenvironment is immunosuppressed 
by several mechanisms, including an accumulation of regulatory T cells, M2 type tumor-
associated macrophages and myeloid-derived suppressor cells (MDSCs). Activated KRAS in 
tumor cells directs the transcription of granulocyte-macrophage colony-stimulating factor (GM-
CSF), an inflammatory cytokine that promotes recruitment and trans-differentiation of myeloid 
progenitor cells into MDSCs which in turn suppress the immune surveillance function of CD8+ 
T cells.(23) Tumor cells also stimulate the expression of IP-10 (CXCL10) in PSCs which attract 
CXCR3+ regulatory T cells to the tumor milieu.(24) PSCs also secrete CXCL12 which attracts 
CD8+ T cells away from the juxtatumoral stromal compartment, reducing their chance to interact 
with cancer cells.(25) In addition, various cell types within the tumor microenvironment secrete 
numerous cytokines that support the immunosuppressive phenotype, including IL-1b, IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-13, TNFα, TGFβ, FGF, PDGF, MMPs, thymic stromal lymphopoietin 
(TSLP), interferon-γ (IFN-γ) and VEGF.(23) Ultimately, the PDAC microenvironment appears 
to constitute a biological space of immune privilege where cancer cells are protected from 
immune surveillance, as opposed to rendering T cells dysfunctional as mechanisms to bypass 
mechanisms of T cell suppression can promote intratumoral infiltration of cytotoxic T cells and 
uncover latent immune responses.(26, 27) Further research on the dynamic intersection of 
pancreatic cancer and its tumor microenvironment is of great clinical importance as it will likely 
provide answers to improving delivery of chemotherapy and developing effective 
immunotherapy. 
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Metabolic Reprogramming 
Successful pancreatic cancer cell survival and proliferation depends on its ability adapt to 
a severely hypoxic and nutrient-deprived tumor microenvironment. Indeed, pancreatic cancer 
cells are known to employ various metabolic changes through mechanisms that are mainly 
driven by the expression of oncogenic KRAS and hypoxia-inducible transcription factor 1α 
(HIF1α).(2) Oncogenic KRAS induces overexpression of glucose transporter 1, hexokinase 1 and 
hexokinase 2, which significantly increases glucose uptake by pancreatic cancer cells. The 
increased levels of glucose are funneled through aerobic glycolysis to provide substrates for ATP 
production such as pyruvate as well as for the synthesis of nucleic acids, proteins, and fatty 
acids. This process in PDAC is uncoupled from the tricyclic acid (TCA) cycle and electron 
transport chain (ETC) via HIF1α-mediated induction of pyruvate dehydrogenase kinase 1, which 
phosphorylates and inactivates pyruvate dehydrogenase, thereby limiting the conversion of 
pyruvate to acetyl-CoA needed for the TCA cycle. The uncoupling of events results in increased 
production of lactate, which in turn becomes an important nutrient for less hypoxic cancer cells, 
and reduces the production of reactive oxygen species by ETC. Moreover, oncogenic KRAS 
promotes macropinocytosis in cancer cells as a major mechanism for the uptake of extracellular 
proteins to meet cellular requirements for glutamine and other amino acids. Similarly, HIF1α 
activates the autophagy-lysosome system, a self-degrative process for cytoplasmic components 
including organelles and macromolecules, to maintain intracellular energy supplies. In xenograft 
mouse models of PDAC, pharmacologic inhibition of these processes substantially delayed 
tumor growth. 
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Immune Response in Pancreatic Cancer is Unclear 
Development of immunotherapies has revolutionized the treatment options for many 
types of cancers, including but not limited to melanoma, renal and lung cancers. These therapies 
rely on potentiating pre-existing tumor-specific T cells by blockade of immune checkpoints, 
which are inhibitory pathways in place to maintain self-tolerance and modulate physiological 
immune responses to minimize collateral tissue injury. The same pathways are exploited by 
tumors to gain immune resistance against tumor-specific T cells. Some cancers, notably PDAC, 
are refractory to immunotherapies, and it remains unclear why. The failure of numerous immune 
checkpoint inhibitors to advance through clinical trials for treatment of PDAC created a 
preconceived notion in the scientific community that PDACs are poorly immunogenic tumors. 
However, an increasing number of studies have now shown prominent T cell infiltrates in the 
vast majority of biopsies from PDAC patients and identified unique neoantigen qualities in long-
term survivors, indicating that a meaningful immune response in PDAC is achievable.(28, 29) 
However, research in this area has been hampered by the lack of pre-clinical physiologic models 
of PDAC that are suited to study anti-tumor immune response.  
Pre-clinical Modeling of Pancreatic Cancer 
“KP-C” (KrasLox-STOP-Lox-G12D; P53Lox-STOP-Lox-R172H/+; Pdx1-Cre) mice have been widely 
used to investigate pancreatic cancer biology. Although this model has been greatly informative 
regarding the genetic landscape of PDAC, it is ill-suited for the study of cancer immunology on 
two levels. First, tumors develop aggressively in these mice, rapidly progressing to fatal 
metastatic disease predominantly by 6 weeks of life. This creates a practical challenge in 
investigating early disease when meaningful tumor-immune cell interactions may occur before 
significant stromal development and/or the onset of other mechanisms of immune 
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suppression.(30) Secondly, pancreatic tumors that develop in these mice are poorly antigenic, 
lacking neoantigen peptides which are critical for mounting anti-tumor T cell responses. In fact, 
depletion of T cells in KP-C mice using anti-CD4 and anti-CD8 antibodies had no effect on the 
progression of murine PDAC nor on the overall survival of these mice.(31) Thus, most 
pancreatic cancer immunology studies have focused on murine and human PDAC cell lines, 
which have their own limitations.(32) Namely, monolayer cell lines lack the structural 
sophistication and functional differentiation of cells seen in vivo, and cannot recapitulate the 
tumor microenvironment in mouse xenograft studies. Cell line-derived three-dimensional 
spheroid cultures attempt to address this issue, but are difficult to propagate in spheroid form, 
limiting longitudinal investigations. Furthermore, none of the cell-line derived models support 
the growth of untransformed, non-neoplastic cells. Instead, they inevitably become monoclonal 
over time by in vitro selection of the most aggressive clones, resulting in a loss of genetic 
heterogeneity seen in primary tumors. Patient-derived xenograft (PDX) mouse models, which are 
established by implanting a piece of surgically resected tissue from a patient under the dermis of 
immunocompromised mouse hosts, are inherently more physiologic but are cost-prohibitive and 
excessively time-consuming, commonly taking upwards of 6 months to generate sufficient sizes 
of mouse colonies, which is outside clinically meaningful timeframes for any approach to 
personalized medicine for most pancreatic cancer patients. 
A recent breakthrough in translational pancreatic cancer research has been the 
development of organoid models of pancreas using human and mouse pancreatic tissues for pre-
clinical modeling of PDAC. Organoids, comprising of complex clusters of multiple cell types 
derived from the tissue of interest, can recapitulate the intricate spatial architecture of the 
progenitor organ structure and perform functions of the organ such as secretion or contraction. 
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Since a robust method for production of self-renewing intestinal organoids was first reported in 
2009, tumor organoid models have been widely adopted for multiple organ systems.(33) In 2015, 
Boj et al. recently described methods for reliably generating human and mouse PDAC organoids 
using surgical resection specimens as well as endoscopic ultrasound-guided fine needle biopsy 
(EUS-FNB) specimens.(34) PDAC organoids derived in this manner could recapitulate the 
natural history of human PDAC when orthotopically transplanted into immunocompromised 
mice, forming early PanIN-like lesions that progressed to invasive pancreatic cancer with robust 
stromal response. The ability to generate organoid cultures from FNB specimens is a major 
advantage, since it enables investigators to capture the full spectrum of PDAC ranging from 
early premalignant lesions to late metastatic cancers, as opposed to surgical resection specimens 
which account for fewer than 20% of patients diagnosed with PDAC who are surgical 
candidates. The organoid model is physiologic yet possesses all the desirable intrinsic properties 
of an in vitro system. PDAC organoid cultures can be propagated in vitro for expansion of 
starting material, which is often the limiting factor for tissue-consuming studies such as deep 
sequencing, and cryopreserved indefinitely without losing genetic heterogeneity. They are highly 
tractable, amenable to genetic manipulation and high-throughput assays. Moreover, in contrast to 
PDX mouse models, organoid cultures can be established rapidly in sufficient quantities for 
studies in just 2-4 weeks from the time point of acquiring patient tissues, permitting a 
personalized approach to pancreatic cancer medicine to investigate patient-specific tumor 
biology, evaluate prognosis and guide therapy in real time. 
II.   STATEMENT OF PURPOSE 
In this study, we sought to develop murine and human organoid models of PDAC to 
investigate the biology of pancreatic cancer immune response. Our aims were mainly two-fold: 
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1. Development of an immunogenic murine PDAC organoid model to study antigen-
specific anti-tumor T cell responses in both in vivo and in vitro setting. 
2. Creation of a clinically annotated library of validated, patient-derived PDAC organoid 
lines as tools for studying human pancreatic cancer immunology. 
III.   METHODS 
Acquisition of human specimens 
Human pancreatic cancer tissues were obtained from patients undergoing endoscopic 
ultrasound-guided fine needle biopsy (EUS-FNB) or surgical resection at Yale New Haven 
Hospital. Some of the surgical resection specimens were used to create patient-derived xenograft 
(PDX) mouse models, which subsequently became available as a secondary source of patient-
derived tissues for generation of organoids. Tissues were determined to be tumoral or normal by 
evaluation of on-site clinical pathologist. Written informed consent was obtained from all 
patients prior to tissue acquisition. This study was reviewed and approved by the Institutional 
Review Board of Yale University. All EUS-FNB specimens were provided by James Farrell who 
also performed the biopsies. All surgical resection specimens were histologically evaluated and 
provided by Marie Robert. PDX mouse models of PDAC were previously established by Ryan 
Sowell in Kaech laboratory. 
Isolation and culture of murine pancreatic organoids 
Murine pancreatic organoids were generated using normal or pre-neoplastic pancreatic 
tissues from C57BL/6 mouse and KP-NINJA (KrasLox-STOP-Lox-G12D; P53flox/flox; inversion induced 
joined neoantigen) mouse, respectively. Detailed procedures for isolation and propagation of 
murine pancreatic organoids were adapted from Boj et al., 2015 and Huch et al., 2016. Briefly, 
mouse pancreas was dissected and minced into sub-millimeter pieces before enzymatic digestion 
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with collagenase XI (0.125 mg/mL, Sigma-Aldrich), dispase II (0.125 mg/mL, Thermo 
Scientific) and DNase I (0.1 mg/mL, Sigma-Aldrich) in advanced DMEM/F12 medium (Life 
Technologies) supplemented with FBS (2.5%), Glutamax (1X, Thermo Scientific) and 
Antibiotic-Antimycotic (1X, Thermo Scientific) for 1-3 hours at 37ºC in a tissue dissociator until 
visual confirmation of pancreatic ducts which were manually picked for ductal enrichment under 
a dissecting microscope. Harvested ductal fragments were embedded in growth factor reduced 
Matrigel (Corning) and cultured in complete murine organoid growth medium, consisting of 
advanced DMEM/F12 supplemented with Glutamax (1X), HEPES (10 mM, Life Technologies) 
and Antibiotic-Antimycotic (1X), Rspo1-conditioned medium (10% v/v), human noggin (0.1 
µg/mL, Peprotech), B27 supplement minus vitamin A (1X, Thermo Scientific), N-acetyl cysteine 
(1.25 mM, Sigma-Aldrich), nicotinamide (10 mM, Sigma-Aldrich), human gastrin I (10 nM, 
Sigma-Aldrich), mouse EGF (50 ng/mL, Thermo Scientific), human FGF-10 (100 ng/mL, 
Peprotech) and A83-01 (500 nM, Tocris Bioscience). Y-27632 (10.5 µM, Tocris Bioscience) 
was added for initial organoid cultures following isolation from primary tissue, single cell 
dissociation, or thawing from cryopreservation. Murine organoid models were characterized by 
in vivo transfer for tumor formation in C57BL/6 mouse and immunohistochemical analysis of 
resulting tumors. KP-NINJA mouse model was previously established by Nikhil Joshi. All 
procedures outlined above were performed by the author. 
Isolation and culture of human PDAC organoids 
Human PDAC organoids were generated using patient-derived tissues from EUS-FNB, 
surgical resection, or pre-established PDX mouse models. Detailed procedures for isolation and 
propagation of human PDAC organoids were adapted from Boj et al., 2015 and Huch et al., 
2016. Briefly, tissues were minced into sub-millimeter pieces before enzymatic digestion with 
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collagenase II (5 mg/mL, Thermo Scientific), dispase II (0.125 mg/mL) and DNase I (0.1 
mg/mL) in advanced DMEM/F12 medium supplemented with FBS (2.5%), Glutamax (1X) and 
Antibiotic-Antimycotic (1X) for 1-3 hours at 37ºC in a tissue dissociator until tissues become 
submacroscopic. Cells are embedded in growth factor reduced Matrigel and cultured in complete 
human organoid growth medium, consisting of advanced DMEM/F12 supplemented with 
Glutamax (1X), HEPES (10 mM) and Antibiotic-Antimycotic (1X), Wnt3a-conditioned medium 
(50% v/v), Rspo1-conditioned medium (10% v/v), human noggin (0.1 µg/mL), N2 supplement 
(1X, Thermo Scientific), B27 supplement minus vitamin A (1X), N-acetyl cysteine (1.25 mM), 
nicotinamide (10 mM), human gastrin I (10 nM), human EGF (50 ng/mL, Peprotech), human 
FGF-10 (100 ng/mL, Peprotech) and A83-01 (500 nM). Y-27632 (10.5 µM) was additionally 
added for initial organoid cultures following isolation from primary tissue, single cell 
dissociation, or thawing from cryopreservation. Human organoid models were characterized by 
Sanger sequencing of KRAS and P53, in vivo transfer for tumor formation in immunodeficient 
NOD scid gamma (NSG) mouse (The Jackson Laboratory) and immunohistochemical analysis of 
resulting tumors. FNB-derived organoid lines were established by the author. Surgical resection-
derived and PDX mouse-derived organoids were established by collaborative effort of Prashanth 
Gokare and the author. Characterization of patient-derived organoids was performed by 
collaborative effort of Prashanth Gokare and the author. 
Isolation of primary murine PDAC cell lines 
Primary murine PDAC cell lines were isolated from pancreatic tumors harvested from 
KP-C (KrasLox-STOP-Lox-G12D; P53flox/flox; Pdx1-Cre) mouse. Resected tumors were minced into 
sub-millimeter pieces before enzymatic digestion with trypsin-EDTA (0.25%, Life 
Technologies) and collagenase IV (1 mg/mL, Worthington Biochemical) in HBSS buffer (1X, 
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Life Technologies) for 30 min at 37ºC in a tissue dissociator, after which the digestion reaction 
was quenched using cold FBS. Cells were passed through a 40 µm filter to prepare single cell 
suspension and washed twice prior to cell culture in complete DMEM. All procedures outlined 
above were performed by Brittany Fitzgerald.  
Genetic manipulation of murine pancreatic organoids 
Murine pre-neoplastic pancreatic organoids isolated from KP-NINJA mouse model were 
in vitro transformed into neoplastic organoids using LV-rtTA-Cre-iRFP670. Detailed procedures 
for genetic manipulation of organoids were adapted from Huch et al., 2016. Briefly, a single cell 
suspension of organoids was prepared by pooling 3 confluent wells of a 24-well plate, removal 
of Matrigel, and digestion of organoids in TrypLE Express (1X, Life Technologies) and DNAse I 
(0.1 mg/mL) for 5 min at 37ºC with vigorous pipetting every 2 min. After washing, cells were 
resuspended with concentrated lentivirus and spinoculated at 600 G for 1 hour at 32ºC, followed 
by incubation for 6 hours at 37ºC. iRFP670 labeling of infected organoid fragments could be 
visualized by fluorescence microscopy 2-3 days after infection. After expansion, organoids were 
analyzed by flow cytometry for expression of iRFP670 and sorted for the brightest 10% of cells 
expressing iRFP670. For the expression of programmed, GFP-tagged neoantigens, a subset of 
transformed organoids was also infected with Ad-FLPo by spinoculation followed by incubation 
as described above. Ad-Cre was used as a negative control. Alternatively, a subset of organoids 
was treated with doxycycline and tamoxifen in vitro to achieve the same effect. After expansion, 
organoids were analyzed by flow cytometry for expression of GFP and sorted for the brightest 
10% of cells expressing GFP. Lentiviral and adenoviral transformations of organoids were 
performed by the author. Creation of immunogenic organoid lines by treatment with doxycycline 
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and tamoxifen was performed by Gena Foster. Flow cytometry and cell sorting of transformed 
organoids were performed by collaborative effort of Gena Foster and the author. 
In vivo mouse assays 
Murine and human pancreatic organoids were characterized by subcutaneous injection of 
organoids for in vivo tumor formation in C57BL/6 mouse or NSG mouse, respectively. To 
standardize injections, organoids were first dissociated into single cells and seeded at 
concentration of 2.5 x104 cells per well in 24-well plate format. Organoids were then expanded 
to 80-90% confluency in a period of 5-10 days depending on the organoid line. For each mouse 
injection, organoids were pooled from 6 confluent wells for a total of approximately 5 x 105 
cells, broken down into organoid fragments by vigorous pipetting using 200 µL pipette tips, and 
finally resuspended in 50 µL of Matrigel diluted 1:1 with cold PBS. Mice were anesthetized 
using isoflurane for injections and subsequently monitored for subcutaneous growth of tumors by 
caliper measurement every 2 days. Mice were euthanized promptly when tumors reached 1 cm in 
size or whenever a humane concern developed. Resulting tumors were harvested and analyzed 
by immunohistochemistry. All procedures outlined above were performed by the author. 
To test the effects of programmed neoantigens on tumor growth in vivo, neoantigen-
negative, neoantigen-positive and weakly neoantigen-positive murine PDAC organoids were 
injected subcutaneously into C57BL/6 mice as described above. For creation of a weakly 
neoantigen-positive organoid line with only 10% of its cells expressing neoantigens, neoantigen-
positive organoids were diluted 1:9 with neoantigen-negative organoids. A cohort of mice also 
received retroorbital injections of luciferase-positive P14 splenocytes 24 hours prior to receiving 
organoid injection for co-transfer of antigen-specific T cells. Splenocytes were harvested from 
luciferase+ P14 mouse strain by homogenizing dissected spleen through a 70 µm strainer and 
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passing through a 27-gauge needle for single cell dissociation. Following centrifugation, RBC 
lysis was performed by incubation of cells in ACK Lysing Buffer (1X, Thermo Scientific) for 3-
5 min at room temperature. Cells were washed twice using RPMI medium prior to flow 
cytometry analysis for confirmation of tetramer-positive P14 CD8+ T cell population. For each 
mouse injection, 1 x 106 splenocytes were finally resuspended in PBS. Mice were anesthetized 
using isoflurane for each injection and subsequently monitored for subcutaneous growth of 
tumors by caliper measurement every 2 days. Mice receiving co-transfer of organoids and 
splenocytes were additionally monitored by IVIS Spectrum In Vivo Imaging System 
(PerkinElmer) for luciferase detection 24 hours after organoid injection and every 3 days 
thereafter. Mice were euthanized when tumors reached 1 cm in size or whenever a humane 
concern developed.  Resulting tumors were harvested and analyzed by immunohistochemistry. 
Creation of immunogenic murine organoid lines and immunohistochemical analyses of resulting 
tumors were performed by collaborative effort of Gena Foster and the author. Isolation, flow 
cytometry and co-transfer of splenocytes were performed by collaborative effort of Brittany 
Fitzgerald and the author. 
Immunohistochemical analysis of tumors 
Primary and organoid-derived pancreatic tumors were analyzed by 
immunohistochemistry. Tissues were fixed in 10% formalin and embedded in paraffin. Sections 
were subject to H&E, RFP (600-401-379, Rockland) 1:1000, E-Cadherin (610182, BD 
Bioscience) 1:500, CK19 (Troma III, developed by Rolf Kemler, Max-Planck Institute of 
Immunobiology, Freiberg, Germany, and obtained from the Hybridoma Bank at the University 
of Iowa, Iowa City, Iowa, USA) 1:1000, Sox9 (AB5535, EMD Millipore) 1:1000, Muc5AC 
(ab212636, Abcam) 1:400, Phospho-Erk (4370S, Cell Signaling Technology) 1:400, and 
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Phospho-Mek (2338S, Cell Signaling Technology) 1:50. Immunohistochemical staining and 
imaging of tumor sections were performed by collaborative effort of Gena Foster and the author. 
Sanger sequencing of organoids 
Patient-derived organoids were sequenced for characteristic mutations in genes KRAS 
and P53 by Sanger sequencing as part of validation pipeline. Genomic DNA was prepared from 
organoids using DNeasy Blood & Tissue Kit (QIAGEN) and quantified using Nanodrop 
spectrophotometer. Regions of gene that are most frequently mutated were PCR amplified and 
sequenced using the same set of primers. Mutations at codons 12 and 13 of KRAS were 
determined by using sense primer: 5’AAAGGTACTGGTGGAGTATTTGATAG and antisense 
primer: 5’ACAAGATTTACCTCTATTGTTGGATC. Mutations at codon 61 of KRAS were 
determined by sense primer: 5’GGAAGCAAGTAGTAATTGATGGAGA and antisense primer: 
5’GCATGGCATTAGCAAAGACTCA. Mutations in exon 5 of P53 were determined using 
sense primer: CAAGCAGTCACAGCACATGA and antisense primer: 
AACCAGCCCTGTCGTCTCT. Mutations in exon 6 of P53 were determined using sense 
primer: CAGGCCTCTGATTCCTCACT and antisense primer: 
AGACCTCAGGCGGCTCATAG. Mutations in exon 7 of P53 were determined using sense 
primer: ATCTCCTAGGTTGGCTCTGA and antisense primer: 
TGGCAAGTGGCTCCTGACCT. Mutations in exon 8 of P53 were determined using sense 
primer: CTCTTTTCCTATCCTGAGTA and antisense primer: CTGCTTGCTTACCCTGCTTA. 
PCR products were purified using QIAquick PCR Purification Kit (QIAGEN) and analyzed by 
gel electrophoresis for correct band size prior to sequencing. All procedures outlined above were 
performed by collaborative effort of Prashanth Gokare and the author. 
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Development of organoid-T cell co-culture model systems 
P14 CD8+ T cells were pre-activated and expanded out from harvested P14 mouse 
splenocytes by incubation of cells with GP33 peptide (0.1 nM, Anaspec) for 1 hour followed by 
incubation with human IL-2 (10 ng/mL, Peprotech) for 72 hours at 37ºC in complete RPMI 
medium supplemented with FBS (10%), HEPES (1X), non-essential amino acids (1X, Life 
Technologies), sodium pyruvate (1X, Life Technologies), 2-mercaptoethanol (55 µM, Sigma-
Aldrich), penicillin-streptomycin (1X, Life Technologies) and Glutamax (1X), followed by 
cytometry confirmation and cell sorting of tetramer-positive P14 CD8+ T cells. Prior to co-
culture, murine PDAC organoids were labeled with Calcein blue, AM (1X, Anaspec) while P14 
CD8+ T cells were doubly labeled with Calcein blue, AM as well as Calcein green, AM (1X, 
Invitrogen). Neoantigen-positive and neoantigen-negative organoids were seeded in 
10/20/30/40/50 uL volumes of Matrigel in 24-well plate format and cultured to 30% confluency. 
Prepared T cells were resuspended in complete RPMI medium at a concentration of 1 x 105 cells 
per 500 uL per well and were added carefully on top of Matrigel plugs after the removal of 
organoid growth medium. Co-cultures were subsequently monitored by live chambered 
fluorescence imaging on EVOS Cell Imaging System (Invitrogen) for 24 hours. All procedures 
outlined above were performed by collaborative effort of Prashanth Gokare and the author. 
IV.   RESULTS 
KP-NINJA mouse model provides substrate for creation of immunogenic murine organoid 
models of PDAC 
To overcome the paucity of neoantigen peptides on pancreatic tumors that develop in 
standard KP-C mouse model and create an immunogenic murine PDAC organoid model, we 
generated pancreatic organoids from “KP-NINJA” (KrasLox-STOP-Lox-G12D; P53flox/flox; inversion 
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induced joined neoantigen) mouse model that has been genetically engineered to express 
glycoproteins GP33-41 and GP61-80 derived from lymphocytic choriomeningitis virus (LCMV) 
as CD8+ and CD4+ T cell neoantigens, respectively (Figure 2A). The neoantigens are tagged to 
the C-terminus of green fluorescent protein (GFP) functioning as a reporter for neoantigen 
expression. In order to ensure tight regulation of its expression, multi-layered genetic and drug-
inducible mechanisms were engineered. This is critical as leaky expression of neoantigens during 
early developmental phase of mouse immune system can result in immune tolerance and loss of 
immunogenicity. The neoantigen cassette is inverted and flanked by non-compatible flippase 
recognition target (FRT) sites, requiring the action of flippase (FLP) recombinase to be properly 
expressed. The expression of FLP recombinase is regulated by a tetracycline response element 
(TRE), which requires reverse tetracycline-controlled transactivator (rtTA) – which can be 
introduced by any tissue specific promoter – plus doxycycline to be transcribed. The entire TRE-
FLP recombinase cassette is floxed, requiring Cre recombinase mediated inversion to become 
poised for transcription. Introduction of Cre recombinase will also recombine KRAS and P53 
resulting in the activation of oncogenic KRAS and deletion of P53 to drive tumorigenesis. 
Finally, FLP recombinase is fused to a mutated ligand binding domain of the human estrogen 
receptor (ER), requiring tamoxiphen to become stabilized and effective in the nucleus. As a 
result, KP-NINJA mouse model enables genetically and pharmacologically inducible expression 
of known neoantigens with precise temporal and spatial control.  
To generate normal pancreatic organoids from KP-NINJA mouse model, we adapted 
methods previously described by Boj et al.(34) Briefly, mouse pancreas dissection is followed by 
mechanical and enzymatic digestion to release ductal fragments, which are manually picked 
under a dissecting microscope for ductal enrichment (Figure 2B). The enriched ductal fragments 
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are then washed and seeded in basement membrane matrix (Matrigel) in 24-well plate format. 
Liquid medium containing essential components for pancreatic organoid culture is then added on 
top of congealed Matrigel plugs. After 5-10 days of tissue culture, budding of ductal fragments 
into spherical organoids can be observed. 
In vitro transformed murine pancreatic organoids form tumors that are histologically 
similar to early lesions found in human PDAC 
For in vitro transformation of KP-NINJA mouse-derived normal pancreatic organoids, a 
lentiviral construct encoding rtTA-Cre-iRFP670 was used for Cre recombinase-mediated 
activation of KRAS oncogene and deletion of P53. iRFP670 was included in the lentiviral 
construct as a fluorescent reporter for the expression of Cre recombinase, thereby labeling any 
transformed cell. Following lentiviral transformation, organoids were analyzed by fluorescence 
imaging and flow cytometry for expression of iRFP670 and sorted for the brightest 10% of cells 
expressing red fluorescent protein (RFP) (Figure 3A-B). Expression of GFP was included in the 
flow cytometry analysis to examine the possibility of undesirable leakiness of neoantigen 
expression, which did not occur in organoids.  
When lentivirus-transformed organoids versus untransformed normal pancreatic 
organoids were injected subcutaneously into the opposite flanks of same mouse, only the 
transformed organoids formed a tumor (Figure 3C). On histology, these tumors had numerous 
infiltrating well-differentiated ductal structures with epithelial lesions consisting of tall columnar 
cells with mucinous cytoplasm that are reminiscent of early lesions seen in human PDAC, as 
well as a robust stromal response with extensive fibrosis (Figure 3D). The ductal structures 
stained positively for RFP confirming transformed organoids as their cell of origin (Figure 4C). 
The stromal compartment did not stain for RFP, indicating that the stromal response is host-
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derived. The ductal structures also stained positively for markers of epithelial and 
pancreaticobiliary origin, including E-cadherin, CK19 and Sox9, as well as for PDAC-associated 
tumor markers, such as Muc5AC and phosphorylated Erk and phosphorylated Mek which are 
downstream targets of oncogene KRAS in the MAPK/ERK signaling pathway.  
The histology of the organoid-derived tumors was comparable to that of primary murine 
pancreatic tumors that spontaneously form in KP-C mice (Figure 3D-E). Murine PDAC cell 
lines were generated from the primary pancreatic tumors of KP-C mice for comparative analysis. 
Tumors derived from injection of PDAC cell lines showed markedly different histology to that of 
tumors derived from injection of transformed organoids, notable for the absence of organized 
ductal structures in cell line-derived tumors, consistent with highly advanced, undifferentiated 
pathology as a result of a known caveat with monolayer cell lines, that is in vitro selection of 
aggressive clones (Figure 3F). Cell line-derived tumors also lacked a stromal response in 
contrast to organoid-derived tumors. 
Serial in vivo transfer of transformed murine pancreatic organoids results in progressively 
more advanced tumors 
We predicted that serial in vivo transfer of transformed organoids in mice by performing 
repeated rounds of organoid generation from tumors derived from organoid injections in a 
sequential fashion would lead to progressively more advanced tumors. After two rounds of in 
vivo transfer, the organoid-derived tumors showed increased features of high-grade dysplasia, 
including enlarged, hyperchromatic nuclei with prominent nucleoli, nuclear crowding and cell 
stacking (Figure 4A-B). Fluorescence imaging of organoids generated from tumors after one 
round of in vivo transfer not only confirmed retention of RFP label but also showed a more 
uniform labeling of organoids indicating in vivo enrichment for Cre recombinase-transformed 
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cells (Figure 4D). After third round of in vivo transfer, the tumors contained noticeably fewer 
organized ductal structures and appeared poorly differentiated. 
Expression of neoantigens in murine PDAC organoids elicits effective immune response in 
mouse 
For creation of immunogenic murine PDAC organoid lines, an adenoviral construct 
encoding FLP recombinase was used to genetically induce expression of GFP-tagged 
neoantigens in transformed organoids (Figure 5A). After adenoviral introduction of FLP 
recombinase, the organoids were analyzed by flow cytometry to confirm GFP expression and 
were sorted for the brightest 10% of cells expressing GFP (Figure 5B). An adenoviral construct 
encoding Cre was used as a negative control. To test whether expression of neoantigens can 
impact tumor growth, neoantigen positive versus neoantigen negative transformed organoids 
were injected subcutaneously into 3 cohorts of mice, where first cohort received neoantigen 
negative organoids, second cohort received neoantigen positive organoids, and third cohort 
received neoantigen positive organoids as well as retroorbital injections of luciferase-positive 
P14 CD8+ T cells, which have been genetically engineered to express the T cell receptor (TCR) 
specific for GP33, 24 hours prior to organoid injections. In vivo imaging of mice at 24 hours 
after organoid injections demonstrated accumulation of luciferase-positive P14 CD8+ T cells at 
the site of organoid injection in the third cohort (Figure 5C). Mice were monitored for 
subcutaneous growth of tumors for up to 30 days. None of the mice that received neoantigen-
positive organoids developed tumors, while all 5 out of 5 mice that received neoantigen-negative 
organoids developed tumors, indicating immune clearance of neoantigen-expressing PDAC 
organoids (Figure 5D). Interestingly, upon injection of a mixture of neoantigen-positive and 
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neoantigen-negative organoids at a ratio of 1:9, tumors were able to form but were heavily 
infiltrated with immune cells on histology (Figure 6). 
Expression of neoantigens in murine PDAC organoids promotes T cell infiltration in T cell-
organoid co-culture model 
Next, we developed a novel three-dimensional co-culture system to study interactions of 
murine T cells and PDAC organoids in vitro. Splenocytes were harvested from congenic P14 
mice that have been genetically engineered to express TCRs specific for GP33, and were treated 
with IL-2 and GP33 peptide for expansion and pre-activation of constituent P14 T cells. 
Splenocytes were then analyzed by flow cytometry and sorted to prepare a pure population of 
pre-activated P14 CD8+ T cells. Cell-permeant live-cell staining dyes were used to distinguish 
cells in co-culture. PDAC organoids were labeled with green-fluorescent calcein AM dye, while 
P14 CD8+ T cells were doubly labeled with green- and blue-fluorescent calcein AM dyes. P14 
CD8+ T cells were then introduced into the liquid medium of either neoantigen-positive or 
neoantigen-negative PDAC organoid cultures which were maintained in Matrigel plugs of 
different sizes to vary the amount of liquid media-Matrigel interface. Co-cultures were 
subsequently monitored under live fluorescence imaging for 24 hours. Within the first hour, 
there was significant clustering of P14 CD8+ T cells at the boundaries of Matrigel plugs which 
appeared to be a physical barrier to T cell entry (Figure 7A). Nonetheless, small yet increasingly 
large fractions of T cells could be observed to penetrate the Matrigel plugs containing 
neoantigen-positive PDAC organoids, such that by 24 hours there was a clearly noticeable 
difference in the amount of T cell infiltration between neoantigen-positive versus neoantigen-
negative PDAC organoid co-cultures (Figure 7B).  
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Assembly of human PDAC organoid library   
To aid investigations of human pancreatic cancer immunology, we sought to build a 
clinically-annotated library of experimentally validated, patient-derived PDAC organoid lines at 
Yale. We obtained patient samples primarily from EUS-FNB specimens but also a smaller 
number of samples from surgical resection specimens and pre-established PDX mouse models of 
PDAC (Figure 8A). From October 2017 to May 2018, we successfully generated 21 patient-
derived organoid lines from 24 FNB specimens, including one liver metastasis, all of which were 
pathology confirmed as PDAC for an overall organoid isolation efficiency of 87.5% (21/24). 
Established organoid cultures were validated as tumor organoids as opposed to normal pancreatic 
contaminants by in vivo transfer of organoids for tumor formation in immunocompromised 
(NSG) mouse, immunohistochemical analysis of organoid-derived tumors for common markers 
of PDAC, and Sanger sequencing of organoids for KRAS and P53, the two most commonly 
mutated genes in PDAC (Figure 8B-E). Under these criteria, 7 out of 9 patient-derived organoid 
lines tested to date have been successfully validated.  
Histology of tumors derived from organoid injections in mice closely matched the 
histology of their corresponding patient-derived primary tissues, confirming that organoids truly 
recapitulate the pathology of their source material (Figure 8C). The degree of dysplasia seen in 
organoid-derived tumors also correlated with the severity of disease of corresponding patients at 
the time of biopsy in three case studies (Fig. 8D). Organoids derived from a patient who had 
borderline resectable disease (Bx120817) formed tumors of moderately differentiated histology 
in agreement with the primary clinical pathology findings. In comparison, organoids derived 
from the primary tumor of a patient who had metastatic disease in the lungs (Bx111417) formed 
less differentiated tumors consisting of numerous disorganized ductal structures with 
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characteristic loss of lumens. Organoids derived from a metastatic lesion in the liver of a patient 
who had liver metastasis (Bx102417) formed the most poorly differentiated tumors with little to 
zero resemblance of normal ductal structures. 
V.   DISCUSSION  
Development of effective immunomodulating therapies in pancreatic cancer remains 
elusive, largely owing to the lack of effective physiologic PDAC model systems for the study of 
biology of immune response against tumor. To fulfill this critical need, we have developed 
transplantable, immunogenic murine organoid models of PDAC that enable investigations of 
antigen-specific, anti-tumor T cell responses. By genetic engineering of inducible mutations in 
KRAS and P53, we were able to recreate the earliest genetic events in pancreatic tumorigenesis 
in vitro, and then follow the progression of disease in vivo after transplantations of organoids in 
mouse. Tumors derived from organoids in this way are histologically similar to early lesions 
found in human PDAC, demonstrating well-differentiated ductal structures infiltrating an 
extensive and dense fibrous stroma. Ability to recapitulate the tumor microenvironment which is 
fundamental to PDAC pathophysiology is essential for studying how stromal components impact 
immune response. Furthermore, by serial in vivo transfer of transformed murine organoids, we 
were able to generate transplantable organoid models that can reliably recreate discrete stages of 
PDAC progression from early precursor lesions to advanced invasive cancer. Recreation of early 
disease is especially critical for capturing meaningful tumor-immune cell interactions as 
immunosuppression is an early event in PDAC.(30) By introducing known T cell neoantigens in 
murine PDAC organoids, we were able to elicit robust and effective immune responses against 
neoantigen-expressing PDAC organoids in mouse transplant studies. High level of neoantigen 
expression in 100% of cells comprising PDAC organoids resulted in complete immune rejection 
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of organoid-derived tumor growth in mouse, whereas a low level of neoantigen expression by 
dilution of neoantigen-positive cells with neoantigen-negative cells by a factor of 10 permitted 
tumor growth albeit with increased immune infiltration, suggesting that both quality and quantity 
of neoantigen affect immune response. The expression of high-quality neoantigens in sufficient 
quantity before the development of an immunosuppressive tumor microenvironment may have 
been key to the successful immune clearance of PDAC organoids in this set-up. To facilitate 
mechanistic studies of antigen-specific T cell responses against tumor, we have developed an in 
vitro three-dimensional co-culture system that recapitulates interactions of T cells and PDAC 
organoids in vitro, where increased T cell infiltration of Matrigel plugs containing neoantigen-
expressing organoids was observed. This system can be readily applied to study tumor organoid 
interactions with other important cell types such as tumor-associated macrophages or cancer-
associated fibroblasts. Ability to generate effective immune responses against tumor using 
organoid models of PDAC challenges the widely conceived notion that PDAC is an inherently 
immunologically cold disease. 
Precision medicine is a newly emerging medical model that accounts for the unique 
biology of each patient, allowing for the development of targeted therapeutics against specific 
molecular mechanisms at play and a personalized approach to disease management based on the 
individual patient’s tumor characteristics. Since the advent of next-generation sequencing, our 
knowledge of biomolecular and genetic aspects of pancreatic cancer has grown exponentially in 
recent years, revealing novel insights into how precision medicine may be actualized, including 
an appreciation for the remarkable heterogeneity of PDAC. Integrated analyses of different 
‘omics’ data sets enabled the categorization of pancreatic tumors into distinct molecular subtypes 
carrying prognostic and predictive values, paving the way to individualized therapy by 
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stratifying patients based on their tumor subtype for specific therapies. However, personalized 
medicine in pancreatic cancer has been difficult achieve due to the short median survival of 
pancreatic cancer patients and long turnaround times of standard PDX models. Development of 
patient-derived organoid models of PDAC has been revolutionary in this regard, as organoids 
can be derived from patients rapidly and analyzed within clinically relevant timeframes. In some 
cases, pharmacotyping of patient-derived organoids to generate drug-sensitivity profiles could be 
completed in as little as 6 weeks.(35) Moreover, organoids can model the full clinical spectrum 
of PDAC as they can be generated using small amounts of tissue from FNB specimens, thus 
removing the barrier to sampling non-surgical patients who account for more than 80% all 
pancreatic cancer patients, as opposed to standard PDX models that require surgical tissues. In 
our study, we have established a clinically annotated library of 30+ patient-derived PDAC 
organoid lines using FNB and surgical specimens. Our efforts to validate each patient-derived 
organoid line by tumor formation in mouse, immunohistochemistry and sequencing have been 
promising.  
Collectively, our data demonstrate that pancreatic organoids are an ideal model for the 
study of pancreatic cancer immune response. Our ongoing work includes using CRISPR/Cas9-
based lentiviral systems in PDAC organoids to test and define genes that impact anti-tumor T 
cell responses with or without addition of immunomodulating agents in both in vitro co-cultures 
and in vivo mouse studies. We are also using organoid models of PDAC to investigate the 
pathogenic role of renalase – a recently discovered cytoprotective secreted flavoprotein that is 
upregulated in chronic pancreatitis and PDAC – and evaluating its potential use as both 
predictive biomarker and a therapeutic target.(36) Continuation of efforts using organoid models 
of PDAC to understand the mechanistic underpinnings of immunomodulating therapies and 
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advance research in pancreatic cancer early detection and precision medicine should accelerate 
improvement of patient outcomes for this deadly disease.  
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VII.   FIGURES 
 
 
 
Figure 1. Genetic evolution of pancreatic cancer. Pancreatic cancer may arise from either the 
development and progression of intraductal papillary mucinous neoplasm (top) or pancreatic 
intraepithelial neoplasm (bottom) as a result of sequential accumulation of characteristic driver 
mutations. This illustration was adapted from REF 37, with permission. 
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Figure 2. Creation of immunogenic murine organoid models of PDAC using KP-NINJA 
mouse model. (A) Schematic representation of major steps involved in the isolation of murine 
pancreatic organoids. (B) Genetic features of KP-NINJA mouse model for Cre-recombinase 
inducible mutation of KRAS and deletion of P53 (top), and multilayered control of inducible 
expression of GFP-tagged T cell neoantigens by Cre recombinase, rtTA-doxycycline and FLPo-
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tamoxifen (bottom). GFP, green fluorescent protein; rtTA, reverse tetracycline-controlled 
transactivator; FLPo, codon-improved flippase recombinase. 
 
 
Figure 3. In vitro transformed murine pancreatic organoids recapitulates features of early 
PDAC in mouse. (A) Neoplastic transformation of murine pancreatic organoids by lentivirus 
encoding rtTA-Cre-iRFP670. Fluorescence imaging confirms RFP labeling of transformed cells 
in organoids. (B) Flow cytometry analysis confirms RFP expression in transformed organoids, 
which were subsequently sorted for the brightest 10% of cells expressing RFP. Leaky expression 
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of GFP-tagged neoantigens is not observed in these organoids. Untransformed organoids were 
used as a negative control. (C) Subcutaneous injection of transformed versus untransformed 
organoids in opposite flanks of mouse results in tumor formation only with transformed 
organoids. (D) H&E of tumor derived from subcutaneous injection transformed organoids in 
mouse. (E) H&E of primary pancreatic tumor from KP-C mouse model. (F) H&E of tumor 
derived from subcutaneous injection of PDAC cell lines generated from KP-C mouse model. 
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Figure 4. Modeling PDAC progression by serial in vivo transfer of transformed murine 
pancreatic organoids. (A) Experimental design for serial in vivo transfer of organoids. (B) 
H&E of organoid-derived tumors after successive rounds of in vivo transfer shows progressively 
more advanced tumors. (C) Immunohistochemical analysis of organoid-derived tumors after one 
round of in vivo transfer. (D) Fluorescence imaging of organoids reveals more uniform RFP 
labeling of organoids after one round of in vivo transfer versus organoids before in vivo transfer, 
indicating in vivo selection of transformed neoplastic organoids 
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Figure 5. High level of neoantigen expression in murine PDAC organoids results in 
rejection of tumor growth in mouse. (A) Experimental design for expression of GFP-tagged 
neoantigens in PDAC organoids by adenovirus encoding FLPo. (B) Flow cytometry analysis 
confirms GFP expression in organoids treated with adenovirus encoding FLPo, which were 
subsequently sorted for the brightest 10% of GFP-positive cells. Organoids treated with 
adenovirus encoding Cre was used as a negative control. (C) Subcutaneous injection of 
neoantigen-positive versus neoantigen-negative transformed organoids. First cohort of mice 
received neoantigen-negative organoids (N=5). Second cohort received neoantigen-positive 
organoids (N=6). Third cohort received neoantigen-positive organoids plus retroorbital injections 
of luciferase-positive P14 CD8+ T cells 24 hours prior to organoid injections (N=3). In vivo 
imaging after 24 hours of organoid injections reveals accumulation of luciferase-positive T cells 
at the site of organoid injections in the third cohort. (D) Mice were monitored for growth of 
tumors for up to 30 days. Tumor growth was observed in all of the mice in the first cohort. There 
was no tumor growth in any mouse in the second or third cohort that received neonantigen-
positive organoids. 
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Figure 6. Low level of neoantigen expression in murine PDAC organoids permits tumor 
growth with increased immune infiltration. (A) A murine PDAC organoid line that expresses 
GFP-tagged T cell neoantigens at a low level was generated by dilution of neoantigen-positive 
organoids with neoantigen-negative organoids. Flow cytometry analysis confirms GFP 
expression in only 10% of the total population. (B) Subcutaneous injection of organoids 
generated from (A) resulted in growth of tumors in mouse. H&E of tumors derived from these 
organoids shows increased immune infiltration compared to tumors derived from neoantigen-
negative organoids. 
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Figure 7. Development of co-culture model system for murine PDAC organoids and T cells. 
(A) P14 CD8+ T cells were sorted from splenocytes of P14 mouse following in vitro expansion 
and pre-activation with IL-2 and GP33 peptide, respectively. Blue calcein dye was used to label 
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prepared T cells and green calcein dye was used to label both T cells and PDAC organoids. T 
cells were introduced to the liquid medium of wells containing either neoantigen-positive or 
neoantigen-negative PDAC organoids which were maintained in Matrigel plugs in 24-well plate 
format. Fluorescence imaging of co-cultures at 1 hour demonstrates prominent clustering of T 
cells at the boundaries of Matrigel plugs. (B) Fluorescence imaging of co-cultures at 24 hours 
reveals evidence of increased T cell infiltration of Matrigel plugs containing neoantigen-positive 
organoids. Images were converted to black and white for better visualization of blue dye. IL, 
interleukin; GP, glycoprotein. 
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Figure 8. Human PDAC organoids form tumors in mouse that are histologically matched to 
patient-derived primary tissues. (A) Schematic overview for the creation of patient-derived 
organoids using different types of primary tissues, including EUS-FNB specimens, surgical 
resection specimens, and tissues from PDX mouse models that were established by implanting a 
piece of surgical resection specimen in mouse. (B) Patient-derived organoids validated by Sanger 
sequencing of organoids for mutations in KRAS and P53, in vivo transfer of organoids for tumor 
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formation in mouse, and IHC analysis of organoid-derived tumors. (C) IHC analyses of tumors 
generated from different types of primary tissues are shown. Row X shows a tumor generated 
from organoids derived from FNB. Row Y shows a tumor directly taken from a PDX mouse 
model. Row Y’ shows a tumor generated from organoids derived from the tumor shown in row 
Y. Tumors shown in rows Y and Y’ were ultimately derived from the same patient and are 
histologically matched. (D) H&E of three additional tumors derived from FNB specimens are 
shown. Bx120817 (left) was derived from the primary tumor of a patient who had borderline 
resectable disease. Bx111417 (middle) was derived from the primary tumor of a patient who had 
metastatic disease. Bx102417 (right) was derived from a metastatic lesion in the liver. (E) Sanger 
sequencing of patient-derived organoids reveals classic G12V mutation in KRAS. PDX060917 
(left) was derived from tissues from a PDX mouse model and Bx011218A (right) was derived 
from an EUS-FNB specimen. EUS-FNB, endoscopic ultrasound-guided fine-needle biopsy; 
PDX, patient-derived xenograft; IHC, immunohistochemistry. 
VIII.   TABLES 
 
Mutated 
gene 
Frequency 
(%) 
Effect of 
mutation 
Cellular process or 
pathway affected 
Biological significance of 
mutation 
KRAS 95 Gain of 
function 
RAS–ERK 
pathway 
 
Ligand-independent cell 
proliferation and survival; 
immunosuppression; metabolic 
alterations 
CDKN2A 90 Loss of 
function 
G1/S transition  G1/S checkpoint failure 
TP53 80-85 Gain of 
function 
DNA damage 
response 
G1/S checkpoint failure; G2/M 
checkpoint failure; apoptosis 
resistance  
SMAD4 55 Loss of 
function 
TGFβ pathway Failure of celluar homeostasis; 
loss of TGFβ- and TP53-mediated 
gene expression  
TGFBR1 ≤10 Loss of 
function 
TGFβ pathway Failure of celluar homeostasis; 
loss of TGFβ- and TP53-mediated 
gene expression 
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TGFBR2 ≤10 Loss of 
function 
TGFβ pathway Failure of celluar homeostasis; 
loss of TGFβ- and TP53-mediated 
gene expression 
ARID1A ≤10 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
ARID1B ≤10 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
ARID2 ≤10 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
KMT2C ≤10 Loss of 
function 
Epigenomic 
reprogramming -
KMT2 
Decreased methylation of H3K4 
KMT2D ≤10 Loss of 
function 
Epigenomic 
reprogramming -
KMT2 
Decreased methylation of H3K4 
KMT2A ≤10 Loss of 
function 
Epigenomic 
reprogramming -
KMT2 
Decreased methylation of H3K4 
SF3B1 ≤10 Altered 
function 
RNA splicing  Loss of polycomb repressive 
complex-mediated transcriptional 
regulation of HOX genes; 
abnormal splicing of pre-mRNA 
PCDH15 ≤10 Loss of 
function 
Homophilic cell 
adhesion  
Disruption of cadherin-mediated 
calcium-dependent cell adhesion 
BRAF ≤5 Gain of 
function 
RAS–ERK 
pathway 
 
Ligand-independent cell 
proliferation and survival; 
immunosuppression; metabolic 
alterations 
APC2 ≤5 Loss of 
function 
G1/S transition  G1/S checkpoint failure 
CHD1 ≤5 Loss of 
function 
G1/S transition  G1/S checkpoint failure 
FBXW7 ≤5 Loss of 
function 
G1/S transition  G1/S checkpoint failure 
ATM ≤5 Loss of 
function 
DNA damage 
response  
G1/S checkpoint failure; G2/M 
checkpoint failure; apoptosis 
resistance 
ACVR1B ≤5 Loss of 
function 
TGFβ pathway Failure of celluar homeostasis; 
loss of TGFβ- and TP53-mediated 
gene expression 
SMAD3 ≤5 Loss of 
function 
TGFβ pathway Failure of celluar homeostasis; 
loss of TGFβ- and TP53-mediated 
gene expression 
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PBRM1 ≤5 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
SMARCA2 ≤5 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
SMARCA4 ≤5 Loss of 
function 
Epigenomic 
reprogramming - 
SWI/SNF 
Loss of regulatory function in 
modulating nucleosomal DNA-
histone interactions  
MKK4 ≤5 Loss of 
function 
Cellular stress 
response 
Failure of JNK signaling; 
disruption of TLR signaling  
ROBO1 ≤5 Loss of 
function 
Axon guidance  Abnormal migration of cells  
ROBO2 ≤5 Loss of 
function 
Axon guidance Abnormal migration of cells  
SLIT ≤5 Loss of 
function 
Axon guidance Abnormal migration of cells  
 
Table 1. Mutational landscape of pancreatic cancer. Commonly mutated genes in PDAC are 
organized by frequency of mutation in PDAC, effect of mutation on gene function, celluar 
process or signaling pathway affected, and biological significance of mutation. This table is a 
summary of data described in greater detail in REF 6. 
